Attached files
| file | filename |
|---|---|
| 10-Q - 10-Q - F-star Therapeutics, Inc. | d134827d10q.htm |
| EX-31.2 - EX-31.2 - F-star Therapeutics, Inc. | d134827dex312.htm |
| EX-10.1 - EX-10.1 - F-star Therapeutics, Inc. | d134827dex101.htm |
| EX-31.1 - EX-31.1 - F-star Therapeutics, Inc. | d134827dex311.htm |
| EX-4.1 - EX-4.1 - F-star Therapeutics, Inc. | d134827dex41.htm |
| EX-32.1 - EX-32.1 - F-star Therapeutics, Inc. | d134827dex321.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of F-star Therapeutics, Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
| (1) | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
| Date: May 17, 2021 | By: | /s/ Darlene Deptula-Hicks | ||||
| Darlene Deptula-Hicks | ||||||
| Chief Financial Officer and Treasurer |